Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 229

1.

Intravitreal therapy for retinal diseases in Norway 2011-2015.

Kristiansen IS, Haugli Bråten R, Jørstad ØK, Moe MC, Saether EM.

Acta Ophthalmol. 2019 Oct 6. doi: 10.1111/aos.14262. [Epub ahead of print]

PMID:
31587508
2.

Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects.

Wisløff T, Mundal LJ, Retterstøl K, Igland J, Kristiansen IS.

Atherosclerosis. 2019 Aug;287:140-146. doi: 10.1016/j.atherosclerosis.2019.06.900. Epub 2019 Jun 14.

PMID:
31280039
3.

Utilization of etoricoxib in dental patients in the Nordic countries: a population-based register study.

Sengupta K, Thygesen LC, Kristiansen IS, Bolin K, Pukkala E, Emneus M, Christensen LB, Ersbøll AK.

Acta Odontol Scand. 2019 Nov;77(8):584-591. doi: 10.1080/00016357.2019.1622037. Epub 2019 Jun 13.

PMID:
31190596
4.

The healthcare costs of treating human papillomavirus-related cancers in Norway.

Hylin H, Thrane H, Pedersen K, Kristiansen IS, Burger EA.

BMC Cancer. 2019 May 7;19(1):426. doi: 10.1186/s12885-019-5596-2.

5.

General population norms for the EQ-5D-3 L in Norway: comparison of postal and web surveys.

Stavem K, Augestad LA, Kristiansen IS, Rand K.

Health Qual Life Outcomes. 2018 Oct 19;16(1):204. doi: 10.1186/s12955-018-1029-1.

6.

Cost-effectiveness analysis of five procedures for great saphenous vein reflux in a Norwegian healthcare setting or societal setting.

Inderhaug E, Schelp CH, Glambek I, Kristiansen IS.

SAGE Open Med. 2018 Sep 24;6:2050312118801709. doi: 10.1177/2050312118801709. eCollection 2018.

7.

Effect of organized mammography screening on breast cancer mortality: A population-based cohort study in Norway.

Møller MH, Lousdal ML, Kristiansen IS, Støvring H.

Int J Cancer. 2019 Feb 15;144(4):697-706. doi: 10.1002/ijc.31832. Epub 2018 Oct 22.

PMID:
30144028
8.

Kristiansen og medarbeidere svarer.

Kristiansen IS, Bugge C, Førde OH.

Tidsskr Nor Laegeforen. 2018 Aug 20;138(12). doi: 10.4045/tidsskr.18.0594. Print 2018 Aug 21. Norwegian. No abstract available.

PMID:
30132600
Free Article
9.

[Does overdiagnoses contribute to high melanoma numbers?].

Kristiansen IS, Bugge C, Førde OH.

Tidsskr Nor Laegeforen. 2018 Jun 26;138(11). doi: 10.4045/tidsskr.17.0600. Print 2018 Jun 26. Norwegian. No abstract available.

10.

Priority-setting in the patients' last years of life.

Kristiansen IS, Bugge C.

Tidsskr Nor Laegeforen. 2018 May 28;138(9). doi: 10.4045/tidsskr.18.0389. Print 2018 May 29. English, Norwegian. No abstract available.

11.

The Screening Illustrator: separating the effects of lead-time and overdiagnosis in mammography screening.

Lousdal ML, Møller MH, Kristiansen IS, Kalager M, Wisløff T, Støvring H.

Eur J Public Health. 2018 Dec 1;28(6):1138-1142. doi: 10.1093/eurpub/cky085.

PMID:
29796623
12.

Are PCSK9 Inhibitors Cost Effective?

Korman MJ, Retterstøl K, Kristiansen IS, Wisløff T.

Pharmacoeconomics. 2018 Sep;36(9):1031-1041. doi: 10.1007/s40273-018-0671-0. Review.

PMID:
29777433
13.

Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia.

Mundal LJ, Igland J, Veierød MB, Holven KB, Ose L, Selmer RM, Wisloff T, Kristiansen IS, Tell GS, Leren TP, Retterstøl K.

Heart. 2018 Oct;104(19):1600-1607. doi: 10.1136/heartjnl-2017-312706. Epub 2018 Apr 5.

14.

An overview of cervical cancer epidemiology and prevention in Scandinavia.

Pedersen K, Fogelberg S, Thamsborg LH, Clements M, Nygård M, Kristiansen IS, Lynge E, Sparén P, Kim JJ, Burger EA.

Acta Obstet Gynecol Scand. 2018 Jul;97(7):795-807. doi: 10.1111/aogs.13313. Epub 2018 Feb 23. Review.

PMID:
29388202
15.

Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.

Pedersen K, Burger EA, Nygård M, Kristiansen IS, Kim JJ.

Eur J Cancer. 2018 Mar;91:68-75. doi: 10.1016/j.ejca.2017.12.018. Epub 2018 Jan 12.

16.

Health Economic Evaluation of Primary Prevention Strategies Against Cardiovascular Disease [Internet].

Wisløff T, Norheim OF, Halvorsen S, Selmer RM, Kristiansen IS.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Dec.

17.

Health Economic Evaluation of Bevacizumab for Metastatic Colorectal Cancer [Internet].

Aaserud M, Kristiansen IS, Neilson AR, Norum J, Sørbye H, Aas E, Klemp Gjertsen M.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2007 Dec.

18.

Primary Prevention of Cardiovascular Disease, with Emphasis on Pharmacological Interventions [Internet].

Håheim LL, Fretheim A, Brørs O, Kjeldsen SE, Kristiansen IS, Madsen S, Njølstad I, Norheim OF, Ose L, Svilaas A, Flottorp S, Thürmer H.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Oct.

19.

Clinical Effectiveness and Cost Effectiveness of Intracoronary Brachytherapy and Drug Eluting Stents [Internet].

Mørland B, Kløw NE, Rotevatn S, Steigen T, Vatne K, Wisløff T, Kristiansen IS, Norderhaug I.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2004.

20.

Costs and Benefits from Replacing Thrombolysis with Percutaneous Coronary Intervention (PCI) [Internet].

Halvorsen S, Kristiansen IS, Linnestad K, Myhre KI, Selmer R, Wisløff T.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2004.

21.

Effect of Oseltamivir (Tamiflu®) for the Prevention and Treatment of Influenza During an Influenza Pandemic [Internet].

Mørland B, Brantsæter AB, Fuglesang JE, Haaheim LR, Løvoll Ø, Salmén R, Sjursen H, Kristiansen IS, Wisløff T, Ørjasæter Elvsaas IK, Nilsen E.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2005.

22.

[Worthless health policy].

Kristiansen IS.

Tidsskr Nor Laegeforen. 2017 Sep 4;137(16). doi: 10.4045/tidsskr.17.0667. Print 2017 Sep 5. Norwegian. No abstract available.

23.

Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.

Burger EA, Pedersen K, Sy S, Kristiansen IS, Kim JJ.

Br J Cancer. 2017 Sep 5;117(6):783-790. doi: 10.1038/bjc.2017.248. Epub 2017 Aug 3.

24.

The impact of methicillin-resistant S. aureus on length of stay, readmissions and costs: a register based case-control study of patients hospitalized in Norway.

Andreassen AES, Jacobsen CM, de Blasio B, White R, Kristiansen IS, Elstrøm P.

Antimicrob Resist Infect Control. 2017 Jul 6;6:74. doi: 10.1186/s13756-017-0232-x. eCollection 2017.

25.

Efficacy and Cost-Effectiveness of Alendronate for the Prevention of Fractures in Postmenopausal Women in Norway [Internet].

Hagen G, Wisløff T, Falch J, Lofthus C, Frihagen F, Wensaas KA, Granum L, Nevjar J, Kristiansen IS, Klemp M.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2011 Aug.

26.

Practice variation in surgical procedures and IUD-insertions among general practitioners in Norway - a longitudinal study.

Pahle AS, Sørli D, Kristiansen IS, Deraas TS, Halvorsen PA.

BMC Fam Pract. 2017 Jan 21;18(1):7. doi: 10.1186/s12875-017-0581-9.

27.

Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing.

Pedersen K, Burger EA, Sy S, Kristiansen IS, Kim JJ.

Gynecol Oncol. 2016 Nov;143(2):326-333. doi: 10.1016/j.ygyno.2016.08.231. Epub 2016 Aug 17.

28.

Predicting Mean Survival Time from Reported Median Survival Time for Cancer Patients.

Lousdal ML, Kristiansen IS, Møller B, Støvring H.

Med Decis Making. 2017 May;37(4):391-402. doi: 10.1177/0272989X16655341. Epub 2016 Jul 10.

PMID:
27353826
29.

Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis.

Pedersen K, Sørbye SW, Kristiansen IS, Burger EA.

BJOG. 2017 Feb;124(3):474-484. doi: 10.1111/1471-0528.14135. Epub 2016 Jun 6.

30.

Influenced from the start: anchoring bias in time trade-off valuations.

Augestad LA, Stavem K, Kristiansen IS, Samuelsen CH, Rand-Hendriksen K.

Qual Life Res. 2016 Sep;25(9):2179-91. doi: 10.1007/s11136-016-1266-x. Epub 2016 Mar 26.

31.

The predicted lifetime costs and health consequences of calcium and vitamin D supplementation for fracture prevention-the impact of cardiovascular effects.

Hagen G, Wisløff T, Kristiansen IS.

Osteoporos Int. 2016 Jun;27(6):2089-98. doi: 10.1007/s00198-016-3495-9. Epub 2016 Feb 4.

PMID:
26846776
32.

Effect of organised mammography screening on stage-specific incidence in Norway: population study.

Lousdal ML, Kristiansen IS, Møller B, Støvring H.

Br J Cancer. 2016 Mar 1;114(5):590-6. doi: 10.1038/bjc.2016.8. Epub 2016 Feb 2.

33.

Using Decision-Analytic Modeling to Isolate Interventions That Are Feasible, Efficient and Optimal: An Application from the Norwegian Cervical Cancer Screening Program.

Pedersen K, Sørbye SW, Burger EA, Lönnberg S, Kristiansen IS.

Value Health. 2015 Dec;18(8):1088-97. doi: 10.1016/j.jval.2015.08.003. Epub 2015 Sep 16.

34.

Healthcare Costs of Rotavirus and Other Types of Gastroenteritis in Children in Norway.

Shin M, Salamanca BV, Kristiansen IS, Flem E.

Pediatr Infect Dis J. 2016 Apr;35(4):e97-e101. doi: 10.1097/INF.0000000000001026.

PMID:
26658381
35.

Trends in stage-specific incidence of prostate cancer in Norway, 1980-2010: a population-based study.

Møller MH, Kristiansen IS, Beisland C, Rørvik J, Støvring H.

BJU Int. 2016 Oct;118(4):547-55. doi: 10.1111/bju.13364. Epub 2015 Nov 24.

36.

Decisions on statin therapy by patients' opinions about survival gains: cross sectional survey of general practitioners.

Halvorsen PA, Aasland OG, Kristiansen IS.

BMC Fam Pract. 2015 Jul 3;16:79. doi: 10.1186/s12875-015-0288-8.

37.

Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.

Kvamme MK, Lie E, Uhlig T, Moger TA, Kvien TK, Kristiansen IS.

Rheumatology (Oxford). 2015 Jul;54(7):1226-35. doi: 10.1093/rheumatology/keu460. Epub 2015 Jan 7.

PMID:
25573840
38.

Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients.

Lundqvist C, Beiske AG, Reiertsen O, Kristiansen IS.

J Neurol. 2014 Dec;261(12):2438-45. doi: 10.1007/s00415-014-7515-4. Epub 2014 Oct 1.

PMID:
25270681
39.

[Re: Why am I not cited?].

Kristiansen IS.

Tidsskr Nor Laegeforen. 2014 Sep 2;134(16):1547. doi: 10.4045/tidsskr.14.0915. eCollection 2014 Sep 2. Norwegian. No abstract available.

40.

Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway.

Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ.

J Infect Dis. 2015 Jan 15;211(2):206-15. doi: 10.1093/infdis/jiu413. Epub 2014 Jul 23.

41.

Health-related quality of life after myocardial infarction, does choice of method make a difference?

Bøhmer E, Kristiansen IS, Arnesen H, Halvorsen S.

Scand Cardiovasc J. 2014 Aug;48(4):216-22. doi: 10.3109/14017431.2014.923581. Epub 2014 Jun 26.

PMID:
24828790
42.

Does the primary screening test influence women's anxiety and intention to screen for cervical cancer? A randomized survey of Norwegian women.

Burger EA, Nygård M, Gyrd-Hansen D, Moger TA, Kristiansen IS.

BMC Public Health. 2014 Apr 15;14:360. doi: 10.1186/1471-2458-14-360.

43.

Communicating risk using absolute risk reduction or prolongation of life formats: cluster-randomised trial in general practice.

Harmsen CG, Kristiansen IS, Larsen PV, Nexøe J, Støvring H, Gyrd-Hansen D, Nielsen JB, Edwards A, Jarbøl DE.

Br J Gen Pract. 2014 Apr;64(621):e199-207. doi: 10.3399/bjgp14X677824.

44.

Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.

Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ.

PLoS One. 2014 Mar 20;9(3):e89974. doi: 10.1371/journal.pone.0089974. eCollection 2014.

45.

Trends in breast cancer stage distribution before, during and after introduction of a screening programme in Norway.

Lousdal ML, Kristiansen IS, Møller B, Støvring H.

Eur J Public Health. 2014 Dec;24(6):1017-22. doi: 10.1093/eurpub/cku015. Epub 2014 Mar 4.

PMID:
24596400
46.

Dynamic modeling of cost-effectiveness of rotavirus vaccination, Kazakhstan.

Freiesleben de Blasio B, Flem E, Latipov R, Kuatbaeva A, Kristiansen IS.

Emerg Infect Dis. 2014 Jan;20(1):29-37. doi: 10.3201/eid2001.130019.

47.

Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid.

Boberg KM, Wisløff T, Kjøllesdal KS, Støvring H, Kristiansen IS.

Aliment Pharmacol Ther. 2013 Oct;38(7):794-803. doi: 10.1111/apt.12435. Epub 2013 Aug 5.

48.

What professional activities do general practitioners find most meaningful? Cross sectional survey of Norwegian general practitioners.

Halvorsen PA, Edwards A, Aaraas IJ, Aasland OG, Kristiansen IS.

BMC Fam Pract. 2013 Mar 23;14:41. doi: 10.1186/1471-2296-14-41.

49.

[The challenges of subject criticism].

Olsen JA, Kristiansen IS, Magnussen J, Norheim OF, Robberstad B.

Tidsskr Nor Laegeforen. 2013 Mar 5;133(5):499. doi: 10.4045/tidsskr.13.0174. Norwegian. No abstract available.

50.

Supplemental Content

Loading ...
Support Center